NanoViricides 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Anil Diwan

최고 경영자

US$432.5k

총 보상

CEO 급여 비율	92.5%
CEO 임기	19.4yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	16.4yrs

최근 관리 업데이트

Recent updates

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

Feb 18

CEO 보상 분석

Anil Diwan 의 보수는 NanoViricides 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$9m
Jun 30 2024	US$432k	US$400k	-US$8m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	n/a	n/a	-US$9m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	US$444k	US$400k	-US$9m
Mar 31 2023	n/a	n/a	-US$7m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	US$509k	US$400k	-US$8m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	n/a	n/a	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	US$583k	US$400k	-US$9m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	n/a	n/a	-US$15m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	US$589k	US$400k	-US$13m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	US$589k	US$400k	-US$8m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	n/a	n/a	-US$8m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	US$740k	US$398k	-US$9m

보상 대 시장: Anil 의 총 보상 ($USD 432.50K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 650.80K ).

보상과 수익: Anil 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Anil Diwan (65 yo)

19.4yrs

테뉴어

US$432,498

보상

Dr. Anil R. Diwan, Ph D., has been the Executive Chairman at NanoViricides, Inc since 2019 and has been its President and Secretary since June 1, 2005. He has been Chairman at NanoViricides, Inc since June...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Anil Diwan	Executive Chairman	19.4yrs	US$432.50k	데이터 없음
Harmon Aronson	Member of Scientific Advisory Board	19.4yrs	데이터 없음	데이터 없음
Paul Marks	Chairman of Scientific Advisory Board	19.4yrs	데이터 없음	데이터 없음
Thomas Lentz	Member of Scientific Advisory Board	16.4yrs	데이터 없음	데이터 없음
Brian Zucker	Independent Director	4yrs	US$40.00k	0.24% $ 36.8k
Makarand Jawadekar	Independent Director	4.8yrs	US$40.00k	0.26% $ 39.0k
Theodore Edward Rokita	Independent Director	4.5yrs	US$40.00k	0.25% $ 38.4k

16.4yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: NNVC 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 16.4 년).

NanoViricides 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

NanoViricides, Inc., Annual General Meeting, Dec 07, 2024

Insufficient new directors

NanoViricides, Inc., Annual General Meeting, Jan 13, 2024

NanoViricides, Inc., Annual General Meeting, Feb 07, 2023

NanoViricides, Inc., Annual General Meeting, Dec 17, 2022

Nanoviricides, Inc. Announces Board Changes

Recent updates

NanoViricides, Inc., Annual General Meeting, Dec 07, 2024

NanoViricides, Inc. Continues Its March Towards a Phase II Clinical Trial of NV-387

NanoViricides, Inc. Provides an Update on Its Clinical Program and Strategy NV-387

NanoViricides, Inc. Announces Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virusilling, Technology Platform Intending to Revolutionize Treatment of Viral Infections

Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon

New major risk - Financial position

NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found

Insufficient new directors

NanoViricides, Inc., Annual General Meeting, Jan 13, 2024

NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2

Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development

Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2

New major risk - Revenue and earnings growth

Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides

Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well

Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

New major risk - Share price stability

Price target decreased by 38% to US$5.25

NanoViricides, Inc., Annual General Meeting, Feb 07, 2023

NanoViricides, Inc., Annual General Meeting, Dec 17, 2022

NanoViricides, Inc. announced delayed annual 10-K filing

NanoViricides, Inc. Reports Advantages Gained by Remdesivir Encapsulation

NanoViricides, Inc.(NYSEAM:NNVC) dropped from Russell Microcap Growth Index

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

New 90-day high: US$5.49

Consultant has left the company

New 90-day high: US$4.43

New 90-day low: US$3.08

Nanoviricides, Inc. Announces Board Changes

NanoViricides, Inc. announced delayed annual 10-K filing

New 90-day low: US$3.81

NanoViricides, Inc. Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

New 90-day low - US$5.57

NanoViricides, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령